Systemic therapies for intrahepatic cholangiocarcinoma

Robin Kate Kelley, John Bridgewater, Gregory J. Gores, Andrew X. Zhu

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Intrahepatic cholangiocarcinoma (iCCA) is a highly lethal hepatobiliary neoplasm whose incidence is increasing. Largely neglected for decades as a rare malignancy and frequently misdiagnosed as carcinoma of unknown primary, considerable clinical and investigative attention has recently been focused on iCCA worldwide. The established standard of care includes first-line (gemcitabine and cisplatin), second-line (FOLFOX) and adjuvant (capecitabine) systemic chemotherapy. Compared to hepatocellular carcinoma, iCCA is genetically distinct with several targetable genetic aberrations identified to date. Indeed, FGFR2 and NTRK fusions, and IDH1 and BRAF targetable mutations have been comprehensively characterised and clinical data is emerging on targeting these oncogenic drivers pharmacologically. Also, the role of immunotherapy has been examined and is an area of intense investigation. Herein, in a timely and topical manner, we will review these advances and highlight future directions of research.

Original languageEnglish (US)
Pages (from-to)353-363
Number of pages11
JournalJournal of hepatology
Volume72
Issue number2
DOIs
StatePublished - Feb 2020

Fingerprint

Cholangiocarcinoma
gemcitabine
Standard of Care
Diagnostic Errors
Immunotherapy
Cisplatin
Hepatocellular Carcinoma
Neoplasms
Therapeutics
Carcinoma
Drug Therapy
Mutation
Incidence
Research

Keywords

  • Adjuvant therapy
  • Checkpoint inhibitors
  • FGFR
  • IDH

ASJC Scopus subject areas

  • Hepatology

Cite this

Systemic therapies for intrahepatic cholangiocarcinoma. / Kelley, Robin Kate; Bridgewater, John; Gores, Gregory J.; Zhu, Andrew X.

In: Journal of hepatology, Vol. 72, No. 2, 02.2020, p. 353-363.

Research output: Contribution to journalReview article

Kelley, Robin Kate ; Bridgewater, John ; Gores, Gregory J. ; Zhu, Andrew X. / Systemic therapies for intrahepatic cholangiocarcinoma. In: Journal of hepatology. 2020 ; Vol. 72, No. 2. pp. 353-363.
@article{4f01289d7bd546a2a3891e8f1d77baf5,
title = "Systemic therapies for intrahepatic cholangiocarcinoma",
abstract = "Intrahepatic cholangiocarcinoma (iCCA) is a highly lethal hepatobiliary neoplasm whose incidence is increasing. Largely neglected for decades as a rare malignancy and frequently misdiagnosed as carcinoma of unknown primary, considerable clinical and investigative attention has recently been focused on iCCA worldwide. The established standard of care includes first-line (gemcitabine and cisplatin), second-line (FOLFOX) and adjuvant (capecitabine) systemic chemotherapy. Compared to hepatocellular carcinoma, iCCA is genetically distinct with several targetable genetic aberrations identified to date. Indeed, FGFR2 and NTRK fusions, and IDH1 and BRAF targetable mutations have been comprehensively characterised and clinical data is emerging on targeting these oncogenic drivers pharmacologically. Also, the role of immunotherapy has been examined and is an area of intense investigation. Herein, in a timely and topical manner, we will review these advances and highlight future directions of research.",
keywords = "Adjuvant therapy, Checkpoint inhibitors, FGFR, IDH",
author = "Kelley, {Robin Kate} and John Bridgewater and Gores, {Gregory J.} and Zhu, {Andrew X.}",
year = "2020",
month = "2",
doi = "10.1016/j.jhep.2019.10.009",
language = "English (US)",
volume = "72",
pages = "353--363",
journal = "Journal of Hepatology",
issn = "0168-8278",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Systemic therapies for intrahepatic cholangiocarcinoma

AU - Kelley, Robin Kate

AU - Bridgewater, John

AU - Gores, Gregory J.

AU - Zhu, Andrew X.

PY - 2020/2

Y1 - 2020/2

N2 - Intrahepatic cholangiocarcinoma (iCCA) is a highly lethal hepatobiliary neoplasm whose incidence is increasing. Largely neglected for decades as a rare malignancy and frequently misdiagnosed as carcinoma of unknown primary, considerable clinical and investigative attention has recently been focused on iCCA worldwide. The established standard of care includes first-line (gemcitabine and cisplatin), second-line (FOLFOX) and adjuvant (capecitabine) systemic chemotherapy. Compared to hepatocellular carcinoma, iCCA is genetically distinct with several targetable genetic aberrations identified to date. Indeed, FGFR2 and NTRK fusions, and IDH1 and BRAF targetable mutations have been comprehensively characterised and clinical data is emerging on targeting these oncogenic drivers pharmacologically. Also, the role of immunotherapy has been examined and is an area of intense investigation. Herein, in a timely and topical manner, we will review these advances and highlight future directions of research.

AB - Intrahepatic cholangiocarcinoma (iCCA) is a highly lethal hepatobiliary neoplasm whose incidence is increasing. Largely neglected for decades as a rare malignancy and frequently misdiagnosed as carcinoma of unknown primary, considerable clinical and investigative attention has recently been focused on iCCA worldwide. The established standard of care includes first-line (gemcitabine and cisplatin), second-line (FOLFOX) and adjuvant (capecitabine) systemic chemotherapy. Compared to hepatocellular carcinoma, iCCA is genetically distinct with several targetable genetic aberrations identified to date. Indeed, FGFR2 and NTRK fusions, and IDH1 and BRAF targetable mutations have been comprehensively characterised and clinical data is emerging on targeting these oncogenic drivers pharmacologically. Also, the role of immunotherapy has been examined and is an area of intense investigation. Herein, in a timely and topical manner, we will review these advances and highlight future directions of research.

KW - Adjuvant therapy

KW - Checkpoint inhibitors

KW - FGFR

KW - IDH

UR - http://www.scopus.com/inward/record.url?scp=85076532438&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85076532438&partnerID=8YFLogxK

U2 - 10.1016/j.jhep.2019.10.009

DO - 10.1016/j.jhep.2019.10.009

M3 - Review article

C2 - 31954497

AN - SCOPUS:85076532438

VL - 72

SP - 353

EP - 363

JO - Journal of Hepatology

JF - Journal of Hepatology

SN - 0168-8278

IS - 2

ER -